You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

CLINICAL TRIALS PROFILE FOR SHINGRIX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SHINGRIX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03771157 ↗ Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors Active, not recruiting University of Rochester Early Phase 1 2019-02-01 The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.
NCT04403139 ↗ VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination Not yet recruiting National Institute on Aging (NIA) Phase 4 2020-09-01 To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
NCT04403139 ↗ VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination Not yet recruiting University of Washington Phase 4 2020-09-01 To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
NCT04523246 ↗ Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Recruiting Oklahoma Medical Research Foundation Early Phase 1 2020-09-01 The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SHINGRIX

Condition Name

Condition Name for SHINGRIX
Intervention Trials
Herpes Zoster 2
Mild Cognitive Impairment 1
Shingles 1
Achalasia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SHINGRIX
Intervention Trials
Herpes Zoster 5
Esophageal Achalasia 1
Leukemia, Lymphoid 1
Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SHINGRIX

Trials by Country

Trials by Country for SHINGRIX
Location Trials
United States 7
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SHINGRIX
Location Trials
Colorado 1
Massachusetts 1
Florida 1
Maryland 1
Oklahoma 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SHINGRIX

Clinical Trial Phase

Clinical Trial Phase for SHINGRIX
Clinical Trial Phase Trials
Phase 4 4
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SHINGRIX
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 3
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SHINGRIX

Sponsor Name

Sponsor Name for SHINGRIX
Sponsor Trials
GlaxoSmithKline 2
National Heart, Lung, and Blood Institute (NHLBI) 1
Holy Cross Hospital, Florida 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SHINGRIX
Sponsor Trials
Other 10
Industry 2
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.